Drug Trial Radar · NCT02817360
NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients
Last checked: Nov 19, 2026Latest source record: Mar 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,400
Planned (sponsor's estimate)
Start
Feb 2016
Primary completion
Dec 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Martin HuelsmannAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purpose and rationale The purpose of this study is to evaluate the effect of high dose Renin-Angiotensin System (RAS)-antagonists and beta-blocker treatment for the primary prevention of cardiac events in a population of patients with Type 2 diabetes mellitus (T2DM) with no evidence of a preexisting cardiac disease. An additional aim is to demonstrate an interaction between concentrations of amino-terminal pro-B type natriuretic peptide (NT-proBNP as a surrogate of imminent cardiac risk) and treatment effects and the economic impact of the intervention overall and in the biomarker stratified subgroups. Primary objective Superiority of high dose treatment with RAS-antagonists and beta-blockers compared to conventional therapy regarding the reduction of unplanned hospitalization or death due to a cardiac event in T2DM patients with a NT-proBNP \> 125pg/ml. There is an additional eye-substudy for Viennese sites only. The purpose of this sub-study is to evaluate the effect of high dose RAS-antagonists and beta blocker treatment on early subclinical signs of diabetic micro-angiopathy and neuropathy. An additional aim will be the evaluation of the possible impact of the cardiovascular risk factor NT-proBNP on the onset and progression of diabetic retinopathy.
Conditions
- Heart Diseases
- Diabetes Mellitus, Type 2
Interventions
RAS-antagonist and beta-blocker up-to maximal dosagesDrug
All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
RAS-antagonist and beta-blocker none or at stable doseOther
All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with an unplanned cardiac hospitalization or death due to a cardiac eventTime frame: 2 years
Locations
21 sites in 5 countries. Site status is shown where the registry gives one.
Krankenanstalt Rudolfstiftung, 1. Medizinische Abteilung
Vienna, Austria · Completed
Zentrum für Klinische Studien
Vienna, Austria · Terminated
Medical University of Vienna Univ.Clinic for Internal Medicine II Department of Cardiology
Vienna, Austria · Recruiting
Univ. Klinik für Innere Medizin III Med. Uni Wien
Vienna, Austria · Recruiting
Universitätsklinik für Augenheilkunde und Optometrie Medizinische Universität Wien
Vienna, Austria · Recruiting
Diabetes & Stoffwechselambulanz Gesundheitszentrum Wien Süd
Vienna, Austria · Recruiting
3. Med. Abtlg., KH Hietzing mit Neurologischem Zentrum Rosenhügel
Vienna, Austria · Terminated
iMED19
Vienna, Austria · Recruiting
Internistische Ordination
Mödling, Lower Austria, Austria · Active not recruiting
Klinischen Abteilung für Endokrinologie und Diabetologie MU Graz
Graz, Styria, Austria · Recruiting
Konventhospital der Barmherzigen Brüder Abteilung für Innere Medizin
Linz, Upper Austria, Austria · Recruiting
Maastricht University Medical Center; Dep. Cardiology
Maastricht, Netherlands · Active not recruiting
Christchurch Heart Institute
Christchurch, New Zealand · Recruiting
Hospital de la Santa Creu i Sant Pau, Unitat de Diabetis, Servei d'Endocrinologia i Nutrició, Universitat Autònoma de Barcelona
Barcelona, Spain · Recruiting
Hospital Universitari Germans Trias i Pujol, l'Institut del Cor
Barcelona, Spain · Recruiting
Ninewells Hospital, Diabetes Support Unit
Dundee, United Kingdom · Recruiting
Queen Elisabeth University Hospital, Glasgow Clinical Research Facility
Glasgow, United Kingdom · Recruiting
North Manchester General Hospital, Diabetes centre
Manchester, United Kingdom · Recruiting
Nethergreen Surgery
Sheffield, United Kingdom · Active not recruiting
Ecclesfield Group Practice
Sheffield, United Kingdom · Active not recruiting
Woodseats Medical Centre
Sheffield, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.